


## Indacaterol maleate

## Chemical Properties

CAS No. :	753498-25-8
Formula:	C <sub>28</sub> H <sub>32</sub> N <sub>2</sub> O <sub>7</sub>
Molecular Weight:	508.56
Appearance:	no data available
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year



## Biological Description

Description	Indacaterol maleate (QAB149) is an ultra-long-acting $\beta$ -adrenoceptor agonist.
Targets(IC <sub>50</sub> )	Adrenergic Receptor
In vitro	Indacaterol inhibits cAMP production in Chinese hamster ovary cells stably transfected with human $\beta$ 2 adrenoceptors with pEC <sub>50</sub> of 8.06. Indacaterol inhibits electrically induced contraction on the electrically stimulated guinea pig trachea in a concentration-dependent manner with pEC <sub>50</sub> of 8.23. Indacaterol induces a concentration-dependent inotropic effect with maximal efficacy of 75% in the isolated guinea pig left atrium. [1] Indacaterol reverses the carbachol-induced contraction in a concentration-dependent manner with IC <sub>50</sub> of 37 nM in human small airways. Indacaterol concentration dependently reverses the serotonin-induced contraction with IC <sub>50</sub> of 10.5 nM in rat small airways. Indacaterol has the highest intrinsic efficacy of 53% in rat small airways and 73% in human small airways. [2] Indacaterol (10 $\mu$ M) induces close to full inhibition of the EFS-induced contraction of isolated human bronchi and the effect lasts 12 hours. [3] Indacaterol inhibits the IgE-dependent release of histamine from mast cells with the intrinsic activity (E <sub>max</sub> of a long-acting Indacaterol/E <sub>max</sub> of Isoprenaline) of 1.03. [4] Indacaterol inhibits cAMP release from human airway smooth muscle with pEC <sub>50</sub> of 8.53 and E <sub>max</sub> of 48%. Indacaterol appears to have a reduced efficacy compared with the CHO-K1 data in the primary ASM cells. [5]
In vivo	Indacaterol (6.7 $\mu$ g/kg) inhibits 5-HT-induced bronchoconstriction with a maximal effect of 85% in the conscious guinea pig. Indacaterol (12.5 $\mu$ g/kg) dose-dependently inhibits methacholine-induced bronchoconstriction with a maximal effect of 85% in the anesthetized rhesus monkey. [1]

## Solubility Information

Solubility	DMSO: 94 mg/mL (184.84 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9663 mL	9.8317 mL	19.6634 mL
5 mM	0.3933 mL	1.9663 mL	3.9327 mL
10 mM	0.1966 mL	0.9832 mL	1.9663 mL
50 mM	0.0393 mL	0.1966 mL	0.3933 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Batram C, et al. J Pharmacol Exp Ther, 2006, 317(2), 762-770.  
Sturton RG, et al. J Pharmacol Exp Ther, 2008, 324(1), 270-275.  
Naline E, et al. Eur Respir J, 2007, 29(3), 575-581.  
Scola AM, et al. Br J Pharmacol, 2009, 158(1), 267-276.  
Sayers I, et al. Br J Pharmacol, 2009, 158(1), 277-286.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use**

Tel:781-999-4286    E\_mail:info@targetmol.com    Address:36 Washington Street,Wellesley Hills,MA 02481